Halozyme Therapeutics, Inc. vs. Protara Therapeutics, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$106.49 +1.08%
VS TARAProtara Therapeutics, Inc. Common Stock
$3.85 +0.92%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | TARA | |
|---|---|---|
| Market Cap | $11.96 billion | $225.74 million |
| Revenue (TTM) | $1.66 billion | $3.14 million |
| Net Income (TTM) | $413.60 million | $-70,015,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | TARA | |
|---|---|---|
| P/E Ratio | 31.05 | — |
| Price / Book | 83.30 | 1.40 |
| Price / Sales | 7.19 | 71.98 |
HALO and TARA split the valuation factors evenly.
Profitability
| HALO | TARA | |
|---|---|---|
| Net Margin | 24.86% | -2232.62% |
| Return on Equity | 288.13% | -43.40% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | TARA | |
|---|---|---|
| Short Interest | 9.79% | 0.01% |
TARA leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, TARA overview, TARA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.